Multiply Labs has successfully raised $75 million in Series B funding aimed at enhancing its robotic systems for automating manual processes in biologics manufacturing. This funding round was led by Dr. Patrick Soon-Shiong and NantWorks, with participation from new investors including AstraZeneca, Lingotto, Teradyne, and Strange Ventures.
The significance of this funding lies in Multiply Labs' commitment to revolutionizing the biologics manufacturing sector through automation. By streamlining manual steps with advanced robotic technology, the company aims to improve efficiency and reduce costs in drug production, which is crucial for meeting the growing demand for biologics.
Looking ahead, industry observers will be keen to see how Multiply Labs utilizes this funding to scale its operations and further develop its robotic systems. No further timeline was disclosed at the time of publication.
Editor's Note
The recent funding round for Multiply Labs highlights a growing trend in the pharmaceutical industry towards automation and robotics. As companies seek to enhance efficiency and reduce production costs, the integration of advanced technologies in drug manufacturing is becoming increasingly critical. Stakeholders should monitor how these developments impact supply chain dynamics and competitive positioning in the market.
Copyright Notice
This briefing is an independently written summary based on publicly available reporting and is provided for industry information and news discovery. The original report and source publication are credited and linked where applicable. RobotToday does not claim ownership of third-party source material.
Rights concerns? If you believe any material in this briefing infringes your copyright or other rights, please contact [email protected] with the relevant URL and details. We will review the matter and take appropriate action where warranted.
Leave a comment